IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract

IMGT/mAb-DB ID	400
INN	sarilumab
INN Number	9476
INN Prop. List	106 (2011)
INN Rec. List	68 (2012)
Common name	REGN88, SAR153191
Proprietary name	KEVZARA®
Species	Homo sapiens
IMGT receptor type	IG
Format (legend)
Receptor identification	IgG1 - kappa
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB	9476
IMGT/3Dstructure-DB
Specificity target name and species	IL6R (interleukin 6 receptor, IL-6R, CD126) [Homo sapiens]
Development Technology	VelocImmune®
Origin clone species
Origin clone name

Company	Regeneron Pharmaceuticals Inc. (Tarrytown NY USA); Sanofi (Paris France)
Expression system
Application	Therapeutic
Clinical domain	Immunology
Mechanism of action
Clinical indication	Rheumatoid arthritis (RA)
Development status	Phase M
Regulatory agency status and year	FDA approval May 22, 2017

Company	Regeneron Pharmaceuticals Inc. (Tarrytown NY USA); Sanofi (Paris France)
Expression system
Application	Therapeutic
Clinical domain	Ophthalmology
Mechanism of action
Clinical indication	Uveitis
Development status	Phase II
Regulatory agency status and year

Company	Regeneron Pharmaceuticals Inc. (Tarrytown NY USA); Sanofi (Paris France)
Expression system
Application	Therapeutic
Clinical domain	Immunology
Mechanism of action
Clinical indication	Ankylosing spondylitis (AS)
Development status	Phase II/III
Regulatory agency status and year

Company	Regeneron Pharmaceuticals Inc. (Tarrytown NY USA); Sanofi (Paris France)
Expression system
Application	Therapeutic
Clinical domain	Rheumatology
Mechanism of action
Clinical indication	Polymyalgia Rheumatica (PMR)
Development status	Phase M
Regulatory agency status and year	FDA approval February 28, 2023

Clinical trials	54 studies found, 25 recruiting
Authority decisions	FDA: (BLA) 761037
External links
IMGT notes	The VelocImmune™ mice technology from Regeneron allows making antibodies that have human variable domains and mouse constant regions. After selection of an antibody with the required specificity, the sequences of the human variable VH and VL domains from the VelocImmune antibody are combined with human constant CH and CL regions, respectively, to generate fully human antibody. On May 6, 2011, Sanofi-Aventis simplified its name to Sanofi.
Biosimilars

Format legend:

IMGT/mAb-DB query | IMGT/mAb-DB documentation